JPM vs MHD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9 and a current price of $11.69 that significantly exceeds both the Graham Number ($9.46) and the Intrinsic Value ($2.17). The fund exhibits critical liquidity distress with a Current Ratio of 0.05 and an unsustainable dividend payout ratio of 230.32%, suggesting that distributions are not supported by earnings. While the fund trades slightly below book value (P/B 0.91), the combination of poor financial health, bearish insider sentiment, and a 0/100 technical trend indicates high risk.
Compare Another Pair
Related Comparisons
JPM vs MHD: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and BlackRock MuniHoldings Fund, Inc. (MHD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.